Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.

Journal of the Endocrine Society·2026

Same author

Device-Induced Thrombosis in Blood-Contacting Medical Devices: Mechanisms and Emerging Prevention Strategies.

Advanced healthcare materials·2026

Same author

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Journal of the Endocrine Society·2026

Same author

Frequently Reported Blood Biomarkers in Sarcopenia Clinical Trials: A Systematic Review and Meta-Analysis.

Aging cell·2026

Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025

Same author

Critical Considerations in the Interpretation of Bone Turnover Marker Data in Hormonal Contraceptive Users. Comment on Tassi et al. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. <i>Pharmaceuticals</i> 2025, <i>18</i>, 61.

Pharmaceuticals (Basel, Switzerland)·2025

Same journal

Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.

American journal of hematology·2026

Same journal

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

American journal of hematology·2026

Same journal

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

American journal of hematology·2026

Same journal

Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

American journal of hematology·2026

Same journal

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

American journal of hematology·2026

Same journal

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 22, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Ecarin based coagulation testing.

Robert C Gosselin¹, Jonathan Douxfils²

¹Davis Health System, Thrombosis and Hemostasis Center, University of California, Sacramento, California.

American Journal of Hematology

|May 1, 2020

Summary

This summary is machine-generated.

Ecarin-based assays offer a reliable method for monitoring direct thrombin inhibitors like dabigatran. These tests, derived from Echis carinatus venom, are valuable for assessing anticoagulant effects in clinical settings.

More Related Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Dec 22, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Area of Science:

Coagulation science
Pharmacology
Clinical laboratory diagnostics

Background:

Ecarin, derived from Echis carinatus venom, activates prothrombin to meizothrombin, leading to clot formation.
Ecarin-based assays have a long history but were traditionally limited to specialized laboratories.
Initially used for monitoring direct thrombin inhibitors unaffected by heparinoids.

Purpose of the Study:

To review the current status and utility of ecarin-based assays for monitoring dabigatran.
To highlight the potential of these assays for assessing other parenteral direct thrombin inhibitors.

Main Methods:

Review of existing literature and clinical applications of ecarin-based assays.
Analysis of assay performance in the context of direct thrombin inhibitor monitoring.

Main Results:

Ecarin-based assays gained prominence with the advent of dabigatran etexilate.
These assays are considered a preferred method for assessing dabigatran's anticoagulant effect.
The methodology is also applicable to parenteral direct thrombin inhibitors like argatroban and bivalirudin.

Conclusions:

Ecarin-based assays are a valuable tool for monitoring direct oral thrombin inhibitors, particularly dabigatran.
These assays provide a reliable method for assessing anticoagulant activity in clinical practice.
Their application extends to parenteral direct thrombin inhibitors, offering broad utility.